Slide 1Surrogate Markers and its role in the Drug Development Process Aloka G. Chakravarty, Ph.D. Director, Biologics Therapeutics Statistical Staff [email protected]…

Slide 1Phase I Trial Designs Jud Blatchford, PhD Colorado School of Public Health January 30 th, 2013 Slide 2 Table of Contents 1.Orientation 2.Introduction 3.Components…

Slide 1 PHYSIOLOGICAL AND LABORATORY MARKERS OF DRUG EFFECT Arthur J. Atkinson, Jr., M.D. Senior Advisor in Clinical Pharmacology Clinical Center, NIH Slide 2 USES OF BIOMARKERS…

Outcomes and AEs Steven R. Cummings, MD Outline: Outcomes Primary and secondary outcomes Surrogate markers Adverse experiences Morbone A company wants help designing a trial…

Biomarkers: Physiological & Laboratory Markers of Drug Effect Janet Woodcock, M.D. Deputy Commissioner and Chief Medical Officer Food and Drug Administration February…

Clinical Trials – Human Gonadotropin Drug Products A Regulatory Perspective Shelley R. Slaughter, M.D., Ph. D. Reproductive Medical Officer Team Leader Division of Reproductive…

Evaluation of Clinical Benefit in Sarcomas: Modern Imaging Modalities Robert S. Benjamin, M.D. Department of Sarcoma Medical Oncology The SARCOMA Center Thank you for your…